EGFR and esophageal squamous cell carcinoma: Several studies demonstrated that ESCC patients with high EGFR expression showed a higher response rate to EGFR inhibitors and monoclonal antibodies against EGFR as well as longer PFS and/or OS than those with low to moderate EGFR expression [106–109], although controversial results have also been reported [110].